Kyowa Hakko Kirin Co. Ltd. is expected to begin commercializing its CCR4-targeting monoclonal antibody in the U.S. in the fourth quarter, after winning the FDA's nod Wednesday for use in two types of non-Hodgkin's lymphoma, including Sezary syndrome (SS), for which it becomes the first approved therapy.